Searching for smart, safe news you can TRUST?
Support safe, smart, REAL journalism. Sign up for our Axios AM & PM newsletters and get smarter, faster.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
A researcher performs a CRISPR/Cas9 process at the Max-Delbrueck-Centre for Molecular Medicine. Photo: Gregor Fischer/picture alliance via Getty Images
Three cancer patients in the U.S. were the first to be safely injected with the gene editing tool CRISPR as a form of immunotherapy to fight their illness, AP reports.
Reality check: It's too soon to know whether the treatment will help, doctors say. The patients, who all failed multiple standard treatments, had varying results after two to three months.
- Two of the patients have multiple myeloma, a blood cancer, and the third has a sarcoma, cancer that forms in connective or soft tissue.
- The treatment deletes three genes that may be stopping the patients' cells from attacking the disease, and then adds ones to help them fight their cancer.
- 15 more patients will receive the treatment and doctors will gauge its safety and efficacy.
The bottom line: Researchers are hoping to use CRISPR to treat some genetic diseases, including its progress in treating sickle-cell anemia.